LENZ Therapeutics, Inc.
LENZ- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001815776
No open-market purchases or sales by LENZ Therapeutics, Inc. insiders were filed in the last 90 days; 145 institutions reported holding it in 13F filings for Q2 2026, worth $197.3M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding LENZ Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 78 | 95 | +17 |
| Shares | 18.7M | 19.9M | +1.13M (+6.0%) |
| Value | $444.8M | $573.2M | +$128.4M (+28.9%) |
New holders (25)
Institutions that held LENZ Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
Sold out (8)
Institutions that held LENZ Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| EcoR1 Capital, LLC | 346,772 | $8.23M |
| Parkman Healthcare Partners LLC | 139,357 | $3.31M |
| Schonfeld Strategic Advisors LLC | 107,300 | $2.55M |
| Squarepoint Ops LLC | 12,654 | $300.4K |
| Raleigh Capital Management Inc. | 500 | $11.9K |
| Planned Solutions, Inc. | 217 | $5.15K |
| SRS Capital Advisors, Inc. | 12 | $285 |
| Capital Performance Advisors LLP | 6 | $142 |